ANKRD17

Across TCGA pan-cancer cohorts, ANKRD17 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ANKRD17 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ANKRD17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD17 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

KIRC, LUAD, and UCEC are the cancer types where ANKRD17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.067	0.789	<.001	24	view →
LUAD	OS	Median	III,IV	0.202	0.688	.002	15	view →
UCEC	DFS	Median	All	0.946	0.822	.006	14	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
LIHC	OS	Median	II,III,IV	0.010	0.716	<.001	12	view →
SKCM	OS	Median	II,III,IV	0.387	0.735	.005	9	view →
SARC	DFS	Median	All	0.158	0.613	.005	6	view →
READ	DFS	Median	All	0.282	0.731	.015	3	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →
HNSC	DFS	Median	All	0.920	0.689	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ANKRD17–KIRC (OS)

Open the KIRC breakdown →